MCRB Seres Therapeutics
- 1.020
- -0.010-0.97%
- 1.020
- 0.0000.00%
Seres Therapeutics News
Novo Nordisk, Flagship to Develop Next-generation Obesity Drugs
Oppenheimer: Maintaining the Seres Therapeutics (MCRB.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $5.00 to $4.00.
Oppenheimer: Maintaining the Seres Therapeutics (MCRB.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $5.00 to $4.00.
Oppenheimer Maintains Outperform on Seres Therapeutics, Lowers Price Target to $4
Oppenheimer analyst Jeff Jones maintains Seres Therapeutics with a Outperform and lowers the price target from $5 to $4.
Seres Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 288.35% Oppenheimer $5 → $4 Maintains Outperform 05/08/2024 482.52% Chardan Capital $8 → $6 Mai
Seres Therapeutics Is Maintained at Buy by Chardan Capital
Seres Therapeutics Is Maintained at Buy by Chardan Capital
Buy Rating Affirmed for Seres Therapeutics Amidst Strong Sales Trajectory and Promising Pipeline
Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating
Seres Therapeutics (MCRB) has an average rating of outperform and price targets ranging from $1.10 to $15, according to analysts polled by Capital IQ. Price: 0.7600, Change: +0.01, Percent Change: +1.
Seres Therapeutics Inc (MCRB) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ...
Seres Therapeutics at Risk of Nasdaq Delisting: A Race Against Time to Bolster Stock Value
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Upstart Holdings, Inc. (NASDAQ:UPST) fell sharply during Wednesday's session after the company reported first-quarter financial results and issued second-quarter revenue guidance below estim
ISUN, DTCK and MXCT Among Mid-day Movers
Seres Therapeutics Shares Are Trading Lower After the Company Reported Q1 Financial Results.
Seres Therapeutics Shares Are Trading Lower After the Company Reported Q1 Financial Results.
12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersMaxCyte (NASDAQ:MXCT) shares rose 26.5% to $4.97 during Wednesday's regular session. The company's market cap stands at $519.4 million. The company's, Q1 earnings came out yesterday. Elanco Ani
Seres Therapeutics | 10-Q: Quarterly report
Nasdaq Down Over 50 Points; Uber Posts Q1 Loss
U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 50 points on Wednesday.Following the market opening Wednesday, the Dow traded down 0.05% to 38,863.85 while the NASDAQ fel
Tivic Health Systems, NewGenIvf Group, Elanco Animal Health Among Healthcare Movers
Seres Therapeutics Reports Q1 2024 Earnings: Surpasses Revenue Estimates
Press Release: Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates Continued market adoption of VOWST(R) with approximately 1,411 patient enrollment forms received, approxi
Seres Therapeutics 1Q Loss/Shr 27c >MCRB
Seres Therapeutics 1Q Loss/Shr 27c >MCRB
Seres Therapeutics 1Q Rev Negative $522,000 >MCRB
Seres Therapeutics 1Q Rev Negative $522,000 >MCRB
Analysis
Price Target
No Data
